Ketamine is currently the only widely available psychedelic medicine; however, due to a lack of coverage by insurance providers, combined with steep costs of treatments, this therapy is still out of reach of many patients who could benefit from it.
That’s why we’ve assembled a panel of some of the leading names in ketamine therapy to discuss ways they have employed to increase access to patients for whom the traditional ketamine therapy costs weren’t financially feasible.
From group therapies to compassionate billing practices, our panelists will cover a number of ways to bring this important medicine within the reach of more patients in need of its therapeutic benefits. We’ll also have time for Q and A at the end so you can interact directly with our panel of experts.
So please join us for a live panel discussion on Thursday, April 29th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterward if you cannot make it to the live event.
The webinar will take place on April 29th. Recordings will be available if you are unable to attend.


